Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon ....

SYNCOM/SE/2026-27 11th August, 2026 Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai (M.H.) 400 001 Mumbai- 400051 BSE CODE:524470 NSE SYMBOL: SYNCOMF Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015- Submission of the Un- Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2026. Dear Sir/Ma’am, This is in continuation of our letter no. SYNCOM/SE/2026-27 dated 6th August, 2026 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026. Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2026, in PDF Format, which were also approved and recommended by the Audit Committee and further approved by the Board of Directors at their meeting held on Tuesday, 11th August 2026. The Board Meeting was commenced at 4:00 P.M. and concluded at 04:45 P.M. The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period. We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company. You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record. Thanking You Yours Faithfully For, SYNCOM FORMULATIONS (INDIA) LIMITED CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: Unaudited Standalone and Consolidated Financial Results and Limited Review Report. SYNGOM FORMULATIONS (lNDIA) LIMITED Regd.off :- T,Niraj lndustrial Estate,Off Mahakali caves Road,Andheri (E) Mumbai-400093 Works:- 256'257, Sector - 1, Pithampur, Dist: Dhar454775 E Mail:- finance@sfil.in, Website:- www.sfll.in, CIN :- L24239MH1988PLC047759 STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 3OTH JUNE 2026 Rs. ln Lakhs excePt EPS S. Particulars Quarter Ended Year Ended 30/06/2026 3'1t0312026 30/06/2025 31t0312026 Unaudited Audited Unaudited Audited 1 levenue from Operations 12465.95 "t3400.03 1 1654.69 48657.28 2 Jther Income 781.80 1422.83 601.97 3096.63 3 Iotal lncome(1+2) '13247.75 14822.86 12256.66 51 753.91 4 EXPEIiSES ( a ) Cost of materials consumed 5877.61 6744.83 5961.30 22093.67 ( b ) Purchases of Stock-in-Trade 1733.09 2015.34 156'l .93 6670.04 ( c ) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress (1036.111 (465.1 I ) (616.3e1 (390.111 ( d ) Employee benefits expense 1716.67 1694.73 1595.44 6708.51 (e)Financecosts 23.04 36.71 23.74 110.48 ( f ) Depreciation and amortization expense 154.03 248.23 134.00 653.23 (g)Otherexpenses 1 588.54 1261 .58 1574.94 5859.27 Totalexpenses(4) 10056.87 1 1 536.31 10234.96 41705.09 5 ,rofit{loss) before exceptional items and tax (3' 4) 3190.88 3286.55 2021.70 1 0048.82 6 :xceptional ltems 0.00 (0.44) 4.13 3.69 7 Profiu(loss) belore tax ( 5 - 6 ) 3190.88 s286.1't 2025.83 1 0052.51 8 I ax expense: 11) Current tax 719.07 716.57 431.60 2270.29 (2) Deferred tax 12.89 1',\2.12 2',t.30 181.42 9 *otit tUoss) for the period from continuing operations (7 2458.92 2457.42 1572.93 7600.80 10 )rofiU(loss) from discontinued operations U.UU U.UU 0.00 U.UU 11 fax expense of discontinued operations 0.00 0.00 0.00 0.00 12 rrofiu(loss) from Discontinued operations (after tax) (1 0-1 1 ) 0.00 0.00 0.00 0.00 13 rrofiU(loss) for the period ( 9 + 12 ) 2458.92 2457.42 1572.93 7600.80 14 f ther Comprehensive lncome q(l)ltems that will not be reclassified to profit or loss 0.00 0.00 0.00 0.00 :il) lncome tax relating to items thatwill not be reclassified to 0.00 rrol'it or loss 0.00 0.00 0.00 3 (l) ltems that will be reclassified to profit or loss 381.87 (995.1 7) 403.84 (360.7s1 lli) lncome tax relating to items that will be reclassifled tc 0.00 crofit or loss 0.00 0.00 0.00 15 total Compretrensive lncome for the period (Xlll+XlV) [Comprising Profit (Loss) and Other Comprehensive lncome for the period) 2840.79 't462.25 1976.77 7240.07 '16 Paid up Share Capital of the Company (Face Value 1/-) 9400.00 9400.00 9400.00 9400.00 17 Reserves excluding revaluation reserves 0.00 0.00 0.00 31830.45 18 Earnings per equity share (for continuing operation): (1) Basic 0.26 0.26 0.17 0.81 (2) Diluted 0.26 0.26 0.17 0.8"1 19 Earnings per equity share (for discontinued operation): (1) Basic 0.00 0.00 0.00 0.00 (2) Diluted 0.00 0.00 0.00 0.00 20 Earnings per equity share (for discontinued & continuing operations) (1) tsasrc 0.26 0.26 0.17 0.81 (2) Diluted 0.26 0.26 0.17 0.81 r lndgrre For, Syncom Formulations (lndia) Limited 11.08.2026 M Ankit Kedarmal Bankda Chairman & Wholetime Director DIN:02359461 SYNCOM FORMULATIONS (lNDlA) LIMITED Regd.Off:- T,Nirai lndustrial Estate,Off Mahakali Caves Road,Andhcri (E) Mumbai-400093 Works:- 256-257. Sector - 1, Pithampur, Dist: Dhatr454775 E Mail: finance@sfil.in, Website: www.sfil.in, CIN :- 124239MH1988PLC047759 STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS FOR THE QUARTER ENDED 3OTH JUNE 2026 Quartei Ended Year to date Ended S. No. Particulars 30t06t2026 31/03/2026 3010612025 3'U03t2026 Unaudited Audited Unaudited Audited Segment Revenue a) Pharmaceuticals Drugs & Formulations 13,135.7€ 14.726.34 12,062.5i 51,274.35 b) Trading of Commodities 27.84 4.03 104.5t 1 10.03 c) Renting of Property 84.13 92.4e 89.5t 369.53 Total Segment Revenue 13,247.71 14,822.8e 12,256.6( 51,753.91 Less: lnter Segmenl Revenue Total lncome '13,247.74 14,822.84 I 2,256.6( s1,753.91 2 Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Phamaceuticals Orugs & Formulations 3,134.5( 3,286.1€ 1,960.5' 9.865.61 b) Trading of Commodities 't.9! (4.3s1 1.3t (2.63) c) Renting of Property 77.4i 40.9! 83.5i 300.01 Total Profit before tax and lnterest 3,21 3.9i 3,322.8i 2,045.41 I 0,162.9r Less: i) lnteresl 23.0t 36.7 23.7' '110.4t ii) Other Un-allo€ble Expenditure Profit bsforo tax 3,1 90.8t 3,286.1 2,OZ1.l 10,052.5 3 (Segment Asset-Segment Liabilitios) Segment Asset a) Phamaceuticals Drugs & Formulations 45,500.0t 43.517.5t 39,302.0( 43 51 r.55 b) Trading of Commodities 4.5t 66.51 259.11 66.51 c) Renting of Property 9.257.21 9,342.0( 4,733.4, 9,342.00 Total Segment Asset 54,76 1.8r 52,926.0t 44,294.71 52,926.0( Un-allocable Assets Net Segment Asset 54,761.8r 52,926.0( 44,294.71 52,926.0( Segment Liabilitiss a) Pharmaceuticls Drugs & Formulations 10,563.2i 11,523.4) 8, t85.8: 11,523.42 b) Trading of Commodities 125( 4.1, 8.3t 4.12 c) Renting of Property 2841 168.0 1 33.3( 168.07 Total Segment Liabilities 1 0,859.9r 1 1,695.6 8,327.5t I 1,695.61 LJn-allocable Liabilities Net Seomont Liabilities 1 0,859.9r I I,695.6', 8,327.5! 11,695.6 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on l 1 /08/2026 These above results have been prepared in compliance with the lndian Accounting Standard (refened to as "lnd nS") as notified prescribed under 2 Seclion 133 of the Companies Act, 2013 read with Companies (lndian Accounting Standards) Rules 2015 as amended from time to lime. The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, parliculars 3 of segment wise results are given as required. As required under Regulation 33 of SEBI (LODR) Regulations, 201 5 the limited review by the Statutory Auditors have been completed for the quafler 4 ended on 3oth June, 2026. The reporl does not have any impact [Showing first 8,000 characters — download PDF for full document]